Hairy cell leukemia other diagnostic studies: Difference between revisions

	Hairy cell leukemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hairy cell leukemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hairy cell leukemia other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hairy cell leukemia other diagnostic studies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hairy cell leukemia other diagnostic studies
CDC on Hairy cell leukemia other diagnostic studies
Hairy cell leukemia other diagnostic studies in the news
Blogs on Hairy cell leukemia other diagnostic studies
Directions to Hospitals Treating Hairy cell leukemia
Risk calculators and risk factors for Hairy cell leukemia other diagnostic studies

VisualWikitext

Latest revision as of 17:23, 8 April 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

Bone marrow biopsy may be helpful in the diagnosis of hairy cell leukimea. Fluorescent in-situ hybridization detects any chromosomal mutations occurring among hairy cell leukemia patients.

Bone marrow biopsy

Bone marrow biopsy may be helpful in the diagnosis of hairy cell leukemia.

Cytogenetic Tests

Fluorescent in-situ hybridization

Detects any chromosomal mutations occurring among hairy cell leukemia patients.

References

Template:WikiDoc Sources

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Hairy cell leukemia}}
-{{CMG}}
+{{CMG}}; {{AE}} {{HL}}; {{GRR}} {{Nat}}
 ==Overview==
+[[Bone marrow biopsy]] may be helpful in the diagnosis of hairy cell leukimea. Fluorescent in-situ hybridization detects any [[chromosomal]] [[mutations]] occurring among hairy cell leukemia patients.
-==Other Diagnostic Studies==
+==Bone marrow biopsy==
+* [[Bone marrow biopsy]] may be helpful in the diagnosis of [[hairy cell leukemia]].
-===Bone marrow biopsy===
+==Cytogenetic Tests==
-Most patients require a [[bone marrow biopsy]] for proper diagnosis.  The bone marrow biopsy is used to confirm the presence of HCL and also the absence of any secondary disease.  Abnormal [[white blood cell]]s bearing hair-like projections from the cytoplasm are seen on [[blood film]] examination or bone marrow biopsy. The diagnosis can be confirmed by viewing the cells with a special stain, known as TRAP, or [[tartrate resistant acid phosphatase]].
+* '''[[Fluorescent in situ hybridization|Fluorescent in-situ hybridization]]'''
+:* Detects any [[chromosomal]] [[mutations]] occurring among [[hairy cell leukemia]] patients.
-<div align="left">
-<gallery heights="175" widths="175">
-Image:Hairy cell leukemia bone marrow 0004.jpg|Hairy cell leukemia bone marrow
-</gallery>
-</div>
-===Flow cytometry===
-It is also possible to definitively diagnose hairy cell leukemia through a [[flow cytometry]] blood test which identifies characteristic proteins on the cell surfaces.  These cancerous cells are larger than normal and positive for [[CD19]], [[CD20]], [[CD22]], [[CD11c]], [[CD25]], [[CD103]], and [[FMC7]].<ref>{{cite web |url=http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2&caseID=54 |title=Clinical Flow Cytometry Case #54 |accessdate=2007-09-07 |format= |work=}}</ref>  Hairy cell leukemia-variant (HCL-V), which shares some characteristics with B cell prolymphocytic leukemia (B-PLL), does not show CD25 (also called the Interleukin-2 receptor, alpha).  As this is relatively new and expensive technology, its adoption by physicians is not uniform, despite the advantages of comfort, simplicity, and safety for the patient when compared to a bone marrow biopsy.
-Because a patient could have more than one similar disease, it is also necessary to rule out the presence of leukemias and lymphomas such as [[Splenic marginal zone lymphoma|SMZL]] or [[B-cell prolymphocytic leukemia|B-PLL]].  The presence of these diseases is easily checked during a flow cytometry test, where they characteristically show different results.<ref>{{cite web |url=http://theoncologist.alphamedpress.org/content/vol11/issue7/images/large/780tbl4.jpeg |title=theoncologist.alphamedpress.org |accessdate=2007-09-07 |format= |work=}}</ref>  Careful review of bone marrow biopsy samples is also reliable for this purpose.
 ==References==
@@ Line 30: / Line 22: @@
 {{WikiDoc Help Menu}}
 {{WikiDoc Sources}}
+ [[Category:Up-To-Date]]
+[[Category:Oncology]]
+[[Category:Medicine]]
+[[Category:Hematology]]
+[[Category:Immunology]]